Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study

被引：0

作者：

Qing Zhou

He-Long Zhang

Li-Yan Jiang

Yuan-Kai Shi

Yuan Chen

Jin-Ming Yu

Cai-Cun Zhou

Yong He

Yan-Ping Hu

Zong-An Liang

Yue-Yin Pan

Wen-Lei Zhuo

Yong Song

Gang Wu

Gong-Yan Chen

You Lu

Cui-Ying Zhang

Yi-Ping Zhang

Ying Cheng

Shun Lu

Chang-Li Wang

Jian-Ying Zhou

Yun-Peng Liu

Jian-Xing He

Jie Wang

Yi-Long Wu

机构：

[1] Guangdong Provincial People’s Hospital,Guangdong Lung Cancer Institute

[2] Guangdong Academy of Medical Sciences,Department of Oncology

[3] Tangdu Hospital,Department of Respiratory Medicine

[4] Fourth Military Medical University,Department of Medical Oncology

[5] Shanghai Chest Hospital,Department of Oncology

[6] Shanghai Jiao Tong University,Department of Radiation Oncology

[7] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology

[8] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Respiratory Medicine

[9] Tongji Hospital of Tongji Medical College,Department of Oncology

[10] Huazhong University of Science and Technology,Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital

[11] Shandong Cancer Hospital Affiliated to Shandong University,Department of Oncology

[12] Shandong Academy of Medical Sciences,Department of Oncology

[13] Shanghai Pulmonary Hospital,Department of Respiration

[14] Tongji University,Cancer Center, Tongji Medical College

[15] Daping Hospital and the Research Institute of Surgery of the Third Military Medical University,Department of Respiration

[16] Hubei Cancer Hospital,Department of Thoracic Oncology, Cancer Center

[17] Sichuan University,Cancer Center

[18] Anhui Medical University,Department of Thoracic Medical Oncology

[19] Xinqiao Hospital,Department of Oncology

[20] The Third Military Medical University,Department of Shanghai Lung Cancer Center

[21] General Hospital of Eastern Theater Command of Chinese People’s Liberation Army,Department of Lung Cancer

[22] Union Hospital,Department of Respiratory Disease, Thoracic Disease Center, First Affiliated Hospital of College of Medicine

[23] Huazhong University of Science and Technology,Department of Medical Oncology

[24] Harbin Medical University Cancer Hospital,Department of Thoracic Surgery, Guangzhou Institute for Respiratory Health

[25] West China Hospital,undefined

[26] Sichuan University,undefined

[27] Inner Mongolia Autonomous Region People’s Hospital,undefined

[28] Zhejiang Cancer Hospital,undefined

[29] Jilin Cancer Hospital,undefined

[30] Shanghai Chest Hospital,undefined

[31] Shanghai Jiaotong University,undefined

[32] Tianjin Medical University Cancer Institute and Hospital,undefined

[33] Zhejiang University,undefined

[34] The First Hospital of China Medical University,undefined

[35] First Affiliated Hospital of Guangzhou Medical University,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷

关键词：

Epidermal growth factor receptor; T790M; Non-small cell lung cancer; Osimertinib; Real-world;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：10771 / 10780

页数：9

共 50 条

[1] Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study
Zhou, Qing
Zhang, He-Long
Jiang, Li-Yan
Shi, Yuan-Kai
Chen, Yuan
Yu, Jin-Ming
Zhou, Cai-Cun
He, Yong
Hu, Yan-Ping
Liang, Zong-An
Pan, Yue-Yin
Zhuo, Wen-Lei
Song, Yong
Wu, Gang
Chen, Gong-Yan
Lu, You
Zhang, Cui-Ying
Zhang, Yi-Ping
Cheng, Ying
Lu, Shun
Wang, Chang-Li
Zhou, Jian-Ying
Liu, Yun-Peng
He, Jian-Xing
Wang, Jie
Wu, Yi-Long
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (12) : 10771 - 10780
[2] ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M-positive non-small cell lung cancer (NSCLC) European subset
Tiseo, M.
Santo, A.
Hochmair, M. J.
Geldart, T.
Metro, G.
Hanrahan, E.
Lamberg, K.
Moran, T.
Nyhus, C.
Paredes, A.
Vansteenkiste, J. F.
Vicente, D.
Miranda, M.
Rigas, J.
de Marinis, F.
ANNALS OF ONCOLOGY, 2018, 29
[3] ASTRIS: A Real World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC
Wu, Y.
Cho, B. C.
Zhou, Q.
Chang, G.
Jiang, L.
Metro, G.
Martin, C.
De Castro, G.
Vansteenkiste, J.
Vicente, D.
Milner, A.
Rigas, J.
Chen, Y.
Provencio, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S358 - S359
[4] ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).
De Marinis, Filippo
Cho, Byoung Chul
Kim, Dong-Wan
Kim, Sang-We
Hochmair, Maximilian J.
Metro, Giulio
Vansteenkiste, Johan F.
Vicente, David
Solomon, Benjamin J.
Cheema, Parneet K.
Freitas, Helano C.
Provencio, Mariano
Chen, Yuh-Min
Wu, Yi-Long
Milner, Alvin
Rigas, James R.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
Zhou, Q.
Zhang, H. -L.
Jiang, L. -Y.
Shi, Y. -K.
Chen, Y.
Yu, J. -M.
Zhou, C. -C.
He, Y.
Hu, Y. -P.
Liang, Z. -A.
Pan, Y. -Y.
Zhuo, W. -L.
Song, Y.
Wu, G.
Chen, G. -Y.
Lu, Y.
Zhang, C. -Y.
Zhang, C. -Y.
Zhang, Y. -P.
Chen, Y.
Lu, S.
Wu, Y. -L.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S430
[6] ASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC)
Cheema, P. K.
Chen, Y-M.
de Marinis, F.
Freitas, H. C.
Kim, S-W.
Milner, A.
Provencio, M.
Rigas, J.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2017, 28
[7] Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis
Cheema, P.
Liu, G.
Burkes, R.
Owen, S.
Yu, J.
Hao, D.
Rothenstein, J.
Martel, S.
Iqbal, M.
Juergens, R.
Lam, W.
Laskin, J.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S803 - S803
[8] ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer
de Marinis, Filippo
Wu, Yi-Long
de Castro Jr, Gilberto
Chang, Gee-Chen
Chen, Yuh-Min
Cho, Byoung Chul
Freitas, Helano C.
Jiang, Liyan
Kim, Sang-We
Martin, Claudio
Metro, Giulio
Provencio, Mariano
Vansteenkiste, Johan
Vicente, David
Zhou, Qing
Miranda, Miguel F.
Bakker, Nicolaas A.
Rigas, James R.
Cheema, Parneet K.
FUTURE ONCOLOGY, 2019, 15 (26) : 3003 - 3014
[9] Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis
Cho, Byoung Chul
Kim, Dong-Wan
Park, Keunchil
Lee, Jong-Seok
Yoo, Seung Soo
Kang, Jin Hyoung
Lee, Sung Yong
Kim, Cheol Hyeon
Jang, Seung Hun
Kim, Young-Chul
Yoon, Hyoung-Kyu
Han, Ji-Youn
Kim, Sang-We
CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (03) : 477 - 482
[10] ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort
Passaro, A.
Metro, G.
Tiseo, M.
Migliorino, M. R.
Santo, A.
Sperandi, F.
Maione, P.
Puppo, G.
Grossi, F.
Parra, H. J. Soto
Borra, G.
Roca, E.
Rocco, D.
Stasi, I.
Galetta, D.
Carta, A. M.
Milella, M.
Fasola, G.
Gebbia, V.
Ferrari, S.
De Marinis, F.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →